Stem definition | Drug id | CAS RN |
---|---|---|
antifungal antibiotics | 1798 | 235114-32-6 |
Dose | Unit | Route |
---|---|---|
0.10 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.30 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.21 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 0.17 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.00 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 16 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 16, 2005 | FDA | FUJISAWA HLTHCARE |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 245.06 | 26.49 | 155 | 6710 | 105390 | 56179812 |
Pre-engraftment immune reaction | 171.39 | 26.49 | 29 | 6836 | 209 | 56284993 |
Human herpesvirus 6 infection | 162.37 | 26.49 | 42 | 6823 | 2640 | 56282562 |
Encephalitis viral | 146.16 | 26.49 | 35 | 6830 | 1600 | 56283602 |
Multiple organ dysfunction syndrome | 115.95 | 26.49 | 75 | 6790 | 52695 | 56232507 |
Cytomegalovirus test positive | 104.40 | 26.49 | 30 | 6835 | 2796 | 56282406 |
Aplastic anaemia | 101.76 | 26.49 | 39 | 6826 | 8889 | 56276313 |
Acute graft versus host disease | 96.96 | 26.49 | 31 | 6834 | 4144 | 56281058 |
Mucormycosis | 96.04 | 26.49 | 28 | 6837 | 2746 | 56282456 |
Aspergillus infection | 93.72 | 26.49 | 35 | 6830 | 7430 | 56277772 |
Sepsis | 92.66 | 26.49 | 99 | 6766 | 139741 | 56145461 |
Bronchopulmonary aspergillosis | 90.26 | 26.49 | 35 | 6830 | 8229 | 56276973 |
Bacterial sepsis | 83.63 | 26.49 | 27 | 6838 | 3722 | 56281480 |
Acute graft versus host disease in skin | 83.60 | 26.49 | 26 | 6839 | 3176 | 56282026 |
Pneumonia fungal | 80.41 | 26.49 | 28 | 6837 | 4865 | 56280337 |
Hepatic function abnormal | 73.12 | 26.49 | 48 | 6817 | 34510 | 56250692 |
Septic shock | 70.95 | 26.49 | 59 | 6806 | 60776 | 56224426 |
Systemic candida | 68.23 | 26.49 | 22 | 6843 | 3019 | 56282183 |
Cytomegalovirus viraemia | 67.91 | 26.49 | 25 | 6840 | 5095 | 56280107 |
Thrombotic microangiopathy | 65.86 | 26.49 | 29 | 6836 | 9382 | 56275820 |
Cytomegalovirus infection | 64.63 | 26.49 | 36 | 6829 | 19260 | 56265942 |
Engraft failure | 61.22 | 26.49 | 13 | 6852 | 342 | 56284860 |
Gastrointestinal fungal infection | 58.91 | 26.49 | 12 | 6853 | 256 | 56284946 |
Pyrexia | 58.03 | 26.49 | 145 | 6720 | 418628 | 55866574 |
Pathogen resistance | 57.07 | 26.49 | 23 | 6842 | 5977 | 56279225 |
Meningoencephalitis herpetic | 55.85 | 26.49 | 15 | 6850 | 1089 | 56284113 |
Liver abscess | 54.21 | 26.49 | 18 | 6847 | 2708 | 56282494 |
Candida infection | 52.70 | 26.49 | 35 | 6830 | 25632 | 56259570 |
Respiratory failure | 52.06 | 26.49 | 61 | 6804 | 95001 | 56190201 |
Off label use | 51.11 | 26.49 | 166 | 6699 | 556014 | 55729188 |
Graft versus host disease | 51.04 | 26.49 | 22 | 6843 | 6759 | 56278443 |
Sinus polyp | 50.63 | 26.49 | 11 | 6854 | 323 | 56284879 |
Systemic mycosis | 50.52 | 26.49 | 14 | 6851 | 1143 | 56284059 |
Enterococcal sepsis | 48.59 | 26.49 | 14 | 6851 | 1316 | 56283886 |
Weissella infection | 47.47 | 26.49 | 7 | 6858 | 17 | 56285185 |
Product use in unapproved indication | 47.16 | 26.49 | 71 | 6794 | 140751 | 56144451 |
Haemophagocytic lymphohistiocytosis | 46.76 | 26.49 | 23 | 6842 | 9549 | 56275653 |
Fatigue | 43.63 | 26.49 | 21 | 6844 | 788531 | 55496671 |
Aspartate aminotransferase increased | 43.55 | 26.49 | 52 | 6813 | 82550 | 56202652 |
Enterobacter infection | 42.61 | 26.49 | 14 | 6851 | 2038 | 56283164 |
Fungaemia | 42.13 | 26.49 | 14 | 6851 | 2110 | 56283092 |
Platelet count decreased | 41.98 | 26.49 | 58 | 6807 | 106325 | 56178877 |
Hypoalbuminaemia | 41.68 | 26.49 | 22 | 6843 | 10577 | 56274625 |
Arthralgia | 41.47 | 26.49 | 6 | 6859 | 501663 | 55783539 |
Plasma cell leukaemia | 41.21 | 26.49 | 12 | 6853 | 1171 | 56284031 |
Geotrichum infection | 41.05 | 26.49 | 10 | 6855 | 491 | 56284711 |
Disseminated intravascular coagulation | 40.66 | 26.49 | 26 | 6839 | 17859 | 56267343 |
Fungal infection | 40.53 | 26.49 | 33 | 6832 | 32960 | 56252242 |
Nasal abscess | 40.41 | 26.49 | 8 | 6857 | 147 | 56285055 |
Biloma | 40.28 | 26.49 | 7 | 6858 | 60 | 56285142 |
Acute myeloid leukaemia recurrent | 38.18 | 26.49 | 12 | 6853 | 1516 | 56283686 |
Encephalitis fungal | 37.85 | 26.49 | 6 | 6859 | 27 | 56285175 |
Chronic graft versus host disease | 36.29 | 26.49 | 14 | 6851 | 3242 | 56281960 |
Epstein-Barr virus associated lymphoproliferative disorder | 36.23 | 26.49 | 12 | 6853 | 1791 | 56283411 |
Pain | 36.12 | 26.49 | 18 | 6847 | 663166 | 55622036 |
Mucosal erosion | 35.71 | 26.49 | 11 | 6854 | 1300 | 56283902 |
Cytokine release syndrome | 35.62 | 26.49 | 20 | 6845 | 10855 | 56274347 |
Alanine aminotransferase increased | 35.35 | 26.49 | 50 | 6815 | 93612 | 56191590 |
Encephalitis Japanese B | 35.24 | 26.49 | 6 | 6859 | 45 | 56285157 |
Enterococcal infection | 34.31 | 26.49 | 17 | 6848 | 7167 | 56278035 |
Neutropenia | 32.19 | 26.49 | 64 | 6801 | 158103 | 56127099 |
Renal impairment | 31.81 | 26.49 | 44 | 6821 | 80669 | 56204533 |
Acute respiratory distress syndrome | 31.38 | 26.49 | 24 | 6841 | 21902 | 56263300 |
Pleural effusion | 31.32 | 26.49 | 45 | 6820 | 85435 | 56199767 |
Trichosporon infection | 30.01 | 26.49 | 7 | 6858 | 285 | 56284917 |
Acute lymphocytic leukaemia recurrent | 29.66 | 26.49 | 11 | 6854 | 2286 | 56282916 |
Cryptosporidiosis infection | 29.30 | 26.49 | 7 | 6858 | 316 | 56284886 |
Acute graft versus host disease in intestine | 28.92 | 26.49 | 10 | 6855 | 1700 | 56283502 |
Aspergillus test positive | 28.83 | 26.49 | 7 | 6858 | 339 | 56284863 |
Varicella zoster virus infection | 28.40 | 26.49 | 11 | 6854 | 2573 | 56282629 |
Fungal sepsis | 28.29 | 26.49 | 9 | 6856 | 1182 | 56284020 |
Pneumonia | 28.23 | 26.49 | 111 | 6754 | 406987 | 55878215 |
Oral fungal infection | 28.17 | 26.49 | 11 | 6854 | 2629 | 56282573 |
Drug ineffective for unapproved indication | 28.03 | 26.49 | 24 | 6841 | 25669 | 56259533 |
Fall | 27.88 | 26.49 | 5 | 6860 | 357505 | 55927697 |
Mixed liver injury | 27.09 | 26.49 | 12 | 6853 | 3932 | 56281270 |
Malaise | 26.90 | 26.49 | 6 | 6859 | 367854 | 55917348 |
Liver disorder | 26.84 | 26.49 | 30 | 6835 | 44340 | 56240862 |
Rash morbilliform | 26.79 | 26.49 | 11 | 6854 | 2996 | 56282206 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 202.04 | 20.14 | 232 | 11049 | 121617 | 31564446 |
Aplastic anaemia | 192.10 | 20.14 | 84 | 11197 | 9119 | 31676944 |
Acute graft versus host disease in skin | 151.45 | 20.14 | 59 | 11222 | 4773 | 31681290 |
Multiple organ dysfunction syndrome | 142.70 | 20.14 | 147 | 11134 | 68056 | 31618007 |
Aspergillus infection | 141.47 | 20.14 | 73 | 11208 | 11455 | 31674608 |
Bronchopulmonary aspergillosis | 140.94 | 20.14 | 77 | 11204 | 13557 | 31672506 |
Candida infection | 103.05 | 20.14 | 67 | 11214 | 16191 | 31669872 |
Disseminated intravascular coagulation | 97.91 | 20.14 | 71 | 11210 | 20466 | 31665597 |
Herpes simplex oesophagitis | 93.46 | 20.14 | 20 | 11261 | 174 | 31685889 |
Cytomegalovirus viraemia | 92.45 | 20.14 | 46 | 11235 | 6679 | 31679384 |
Graft versus host disease | 89 | 20.14 | 52 | 11229 | 10395 | 31675668 |
Acute graft versus host disease in intestine | 86.84 | 20.14 | 33 | 11248 | 2493 | 31683570 |
Acute graft versus host disease | 84.32 | 20.14 | 42 | 11239 | 6111 | 31679952 |
Mucormycosis | 79.24 | 20.14 | 39 | 11242 | 5531 | 31680532 |
Fungaemia | 78.04 | 20.14 | 30 | 11251 | 2339 | 31683724 |
Trichosporon infection | 76.94 | 20.14 | 22 | 11259 | 675 | 31685388 |
Fungal infection | 68.64 | 20.14 | 50 | 11231 | 14501 | 31671562 |
Cystitis haemorrhagic | 66.32 | 20.14 | 34 | 11247 | 5255 | 31680808 |
Venoocclusive liver disease | 63.41 | 20.14 | 37 | 11244 | 7375 | 31678688 |
Fusarium infection | 63.30 | 20.14 | 21 | 11260 | 1065 | 31684998 |
Cytomegalovirus test positive | 62.74 | 20.14 | 29 | 11252 | 3576 | 31682487 |
Product use in unapproved indication | 62.47 | 20.14 | 120 | 11161 | 99051 | 31587012 |
Respiratory failure | 61.76 | 20.14 | 121 | 11160 | 101328 | 31584735 |
Pyrexia | 61.07 | 20.14 | 241 | 11040 | 303599 | 31382464 |
Acute graft versus host disease in liver | 54.25 | 20.14 | 20 | 11261 | 1388 | 31684675 |
Sepsis | 53.47 | 20.14 | 146 | 11135 | 151783 | 31534280 |
Pre-engraftment immune reaction | 52.22 | 20.14 | 11 | 11270 | 88 | 31685975 |
Fatigue | 51.09 | 20.14 | 28 | 11253 | 335178 | 31350885 |
Acute myeloid leukaemia recurrent | 51.07 | 20.14 | 21 | 11260 | 1953 | 31684110 |
Septic shock | 49.13 | 20.14 | 86 | 11195 | 66072 | 31619991 |
Cytomegalovirus infection | 47.52 | 20.14 | 51 | 11230 | 24656 | 31661407 |
Systemic candida | 47.38 | 20.14 | 23 | 11258 | 3163 | 31682900 |
Cytokine release syndrome | 46.25 | 20.14 | 42 | 11239 | 16600 | 31669463 |
Glomerulosclerosis | 46.11 | 20.14 | 15 | 11266 | 715 | 31685348 |
Human herpesvirus 6 infection | 44.53 | 20.14 | 19 | 11262 | 1938 | 31684125 |
Mucosal inflammation | 44.52 | 20.14 | 58 | 11223 | 34369 | 31651694 |
Dizziness | 43.47 | 20.14 | 9 | 11272 | 199138 | 31486925 |
Enterococcal infection | 43.45 | 20.14 | 31 | 11250 | 8700 | 31677363 |
Chronic graft versus host disease | 43.14 | 20.14 | 24 | 11257 | 4368 | 31681695 |
Staphylococcal sepsis | 42.18 | 20.14 | 31 | 11250 | 9106 | 31676957 |
Botulism | 41.14 | 20.14 | 10 | 11271 | 160 | 31685903 |
Hepatic function abnormal | 40.69 | 20.14 | 61 | 11220 | 41161 | 31644902 |
Off label use | 39.51 | 20.14 | 234 | 11047 | 347040 | 31339023 |
Encephalitis viral | 39.31 | 20.14 | 15 | 11266 | 1145 | 31684918 |
Candida sepsis | 38.95 | 20.14 | 15 | 11266 | 1174 | 31684889 |
Pneumonia fungal | 37.45 | 20.14 | 25 | 11256 | 6304 | 31679759 |
Drug ineffective | 36.65 | 20.14 | 253 | 11028 | 395320 | 31290743 |
Systemic mycosis | 35.98 | 20.14 | 15 | 11266 | 1444 | 31684619 |
Haemophagocytic lymphohistiocytosis | 35.48 | 20.14 | 31 | 11250 | 11647 | 31674416 |
Thymus hypoplasia | 34.63 | 20.14 | 9 | 11272 | 191 | 31685872 |
Lymphoid tissue hypoplasia | 34.63 | 20.14 | 9 | 11272 | 191 | 31685872 |
Disseminated aspergillosis | 34 | 20.14 | 11 | 11270 | 515 | 31685548 |
Fall | 33.86 | 20.14 | 12 | 11269 | 186077 | 31499986 |
Sinusitis fungal | 33.30 | 20.14 | 11 | 11270 | 550 | 31685513 |
Cerebral aspergillosis | 33.23 | 20.14 | 14 | 11267 | 1384 | 31684679 |
Cholestatic liver injury | 31.77 | 20.14 | 15 | 11266 | 1939 | 31684124 |
Bacteraemia | 31.47 | 20.14 | 35 | 11246 | 17599 | 31668464 |
Graft versus host disease in gastrointestinal tract | 31.43 | 20.14 | 18 | 11263 | 3461 | 31682602 |
Kidney fibrosis | 30.68 | 20.14 | 15 | 11266 | 2095 | 31683968 |
Disseminated cryptococcosis | 30.27 | 20.14 | 13 | 11268 | 1347 | 31684716 |
Geotrichum infection | 30.24 | 20.14 | 10 | 11271 | 502 | 31685561 |
Tumour lysis syndrome | 30.00 | 20.14 | 32 | 11249 | 15353 | 31670710 |
Cystitis viral | 29.94 | 20.14 | 10 | 11271 | 518 | 31685545 |
Necrotising oesophagitis | 29.94 | 20.14 | 10 | 11271 | 518 | 31685545 |
Myocardial infarction | 29.64 | 20.14 | 3 | 11278 | 113451 | 31572612 |
Drug resistance | 29.51 | 20.14 | 39 | 11242 | 23414 | 31662649 |
Immunosuppressant drug level increased | 29.18 | 20.14 | 20 | 11261 | 5265 | 31680798 |
Mucosal disorder | 28.77 | 20.14 | 13 | 11268 | 1521 | 31684542 |
Graft versus host disease in skin | 28.26 | 20.14 | 17 | 11264 | 3580 | 31682483 |
Idiopathic pneumonia syndrome | 28.21 | 20.14 | 8 | 11273 | 238 | 31685825 |
Rhinocerebral mucormycosis | 28.03 | 20.14 | 9 | 11272 | 411 | 31685652 |
Delayed graft function | 27.44 | 20.14 | 14 | 11267 | 2141 | 31683922 |
Engraft failure | 27.40 | 20.14 | 9 | 11272 | 442 | 31685621 |
Platelet count decreased | 27.40 | 20.14 | 94 | 11187 | 110341 | 31575722 |
Pseudomembranous colitis | 27.21 | 20.14 | 15 | 11266 | 2680 | 31683383 |
Renal failure | 27.21 | 20.14 | 101 | 11180 | 123229 | 31562834 |
Product dose omission issue | 27.05 | 20.14 | 3 | 11278 | 105583 | 31580480 |
Vascular device infection | 26.91 | 20.14 | 16 | 11265 | 3299 | 31682764 |
Klebsiella infection | 26.33 | 20.14 | 22 | 11259 | 7781 | 31678282 |
Enterococcal sepsis | 25.64 | 20.14 | 12 | 11269 | 1521 | 31684542 |
Reactive gastropathy | 25.37 | 20.14 | 7 | 11274 | 188 | 31685875 |
Pseudomonal sepsis | 24.84 | 20.14 | 15 | 11266 | 3181 | 31682882 |
Functional gastrointestinal disorder | 24.61 | 20.14 | 13 | 11268 | 2135 | 31683928 |
Device related sepsis | 24.26 | 20.14 | 14 | 11267 | 2730 | 31683333 |
Ophthalmic vein thrombosis | 23.52 | 20.14 | 5 | 11276 | 42 | 31686021 |
Thrombotic microangiopathy | 22.89 | 20.14 | 22 | 11259 | 9329 | 31676734 |
Somnolence | 22.72 | 20.14 | 4 | 11277 | 99441 | 31586622 |
Liver disorder | 22.52 | 20.14 | 39 | 11242 | 29668 | 31656395 |
Infection | 22.32 | 20.14 | 72 | 11209 | 81859 | 31604204 |
Bacterial toxaemia | 22.27 | 20.14 | 6 | 11275 | 147 | 31685916 |
Depression | 22.23 | 20.14 | 3 | 11278 | 90812 | 31595251 |
Antithrombin III decreased | 21.99 | 20.14 | 7 | 11274 | 311 | 31685752 |
Haemorrhagic necrotic pancreatitis | 21.44 | 20.14 | 6 | 11275 | 170 | 31685893 |
Alternaria infection | 21.41 | 20.14 | 7 | 11274 | 339 | 31685724 |
Cerebral ventricle collapse | 21.33 | 20.14 | 5 | 11276 | 68 | 31685995 |
Engraftment syndrome | 21.26 | 20.14 | 9 | 11272 | 900 | 31685163 |
Arthralgia | 21.09 | 20.14 | 14 | 11267 | 151410 | 31534653 |
Weight decreased | 20.69 | 20.14 | 16 | 11265 | 159936 | 31526127 |
Blood beta-D-glucan increased | 20.36 | 20.14 | 7 | 11274 | 396 | 31685667 |
Neurological symptom | 20.31 | 20.14 | 14 | 11267 | 3717 | 31682346 |
Pain in extremity | 20.26 | 20.14 | 8 | 11273 | 116195 | 31569868 |
Blood bilirubin increased | 20.23 | 20.14 | 41 | 11240 | 35095 | 31650968 |
Blast cell count increased | 20.20 | 20.14 | 9 | 11272 | 1018 | 31685045 |
Adenoviral haemorrhagic cystitis | 20.18 | 20.14 | 7 | 11274 | 407 | 31685656 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Febrile neutropenia | 397.37 | 21.56 | 354 | 16679 | 203964 | 70707447 |
Aplastic anaemia | 292.13 | 21.56 | 120 | 16913 | 16596 | 70894815 |
Aspergillus infection | 228.94 | 21.56 | 103 | 16930 | 17765 | 70893646 |
Multiple organ dysfunction syndrome | 222.34 | 21.56 | 194 | 16839 | 108321 | 70803090 |
Pre-engraftment immune reaction | 207.78 | 21.56 | 40 | 16993 | 301 | 70911110 |
Bronchopulmonary aspergillosis | 201.03 | 21.56 | 99 | 16934 | 20903 | 70890508 |
Human herpesvirus 6 infection | 177.67 | 21.56 | 60 | 16973 | 4799 | 70906612 |
Mucormycosis | 176.46 | 21.56 | 68 | 16965 | 7946 | 70903465 |
Encephalitis viral | 168.51 | 21.56 | 49 | 16984 | 2393 | 70909018 |
Cytomegalovirus viraemia | 154.90 | 21.56 | 69 | 16964 | 11616 | 70899795 |
Acute graft versus host disease | 148.05 | 21.56 | 63 | 16970 | 9499 | 70901912 |
Candida infection | 142.88 | 21.56 | 94 | 16939 | 34379 | 70877032 |
Acute graft versus host disease in skin | 130.66 | 21.56 | 53 | 16980 | 7084 | 70904327 |
Sepsis | 130.06 | 21.56 | 220 | 16813 | 244325 | 70667086 |
Product use in unapproved indication | 121.52 | 21.56 | 195 | 16838 | 207283 | 70704128 |
Disseminated intravascular coagulation | 121.04 | 21.56 | 84 | 16949 | 33514 | 70877897 |
Fungaemia | 113.10 | 21.56 | 41 | 16992 | 4041 | 70907370 |
Trichosporon infection | 111.43 | 21.56 | 29 | 17004 | 932 | 70910479 |
Cytomegalovirus infection | 108.37 | 21.56 | 84 | 16949 | 39674 | 70871737 |
Fungal infection | 108.36 | 21.56 | 82 | 16951 | 37385 | 70874026 |
Systemic candida | 104.98 | 21.56 | 43 | 16990 | 5891 | 70905520 |
Graft versus host disease | 104.01 | 21.56 | 57 | 16976 | 14966 | 70896445 |
Pyrexia | 100.95 | 21.56 | 347 | 16686 | 606605 | 70304806 |
Respiratory failure | 97.93 | 21.56 | 158 | 16875 | 168577 | 70742834 |
Hepatic function abnormal | 97.76 | 21.56 | 100 | 16933 | 67896 | 70843515 |
Septic shock | 95.54 | 21.56 | 126 | 16907 | 112132 | 70799279 |
Pneumonia fungal | 95.45 | 21.56 | 47 | 16986 | 9906 | 70901505 |
Cytomegalovirus test positive | 90.96 | 21.56 | 38 | 16995 | 5470 | 70905941 |
Herpes simplex oesophagitis | 88.81 | 21.56 | 20 | 17013 | 343 | 70911068 |
Acute graft versus host disease in intestine | 86.21 | 21.56 | 33 | 17000 | 3783 | 70907628 |
Fatigue | 84.05 | 21.56 | 47 | 16986 | 824272 | 70087139 |
Enterococcal infection | 78.61 | 21.56 | 47 | 16986 | 14535 | 70896876 |
Cytokine release syndrome | 74.47 | 21.56 | 57 | 16976 | 26410 | 70885001 |
Systemic mycosis | 72.37 | 21.56 | 26 | 17007 | 2496 | 70908915 |
Venoocclusive liver disease | 69.76 | 21.56 | 39 | 16994 | 10639 | 70900772 |
Platelet count decreased | 69.00 | 21.56 | 140 | 16893 | 178082 | 70733329 |
Geotrichum infection | 68.40 | 21.56 | 20 | 17013 | 995 | 70910416 |
Acute myeloid leukaemia recurrent | 67.52 | 21.56 | 26 | 17007 | 3028 | 70908383 |
Arthralgia | 67.03 | 21.56 | 19 | 17014 | 503371 | 70408040 |
Haemophagocytic lymphohistiocytosis | 65.89 | 21.56 | 47 | 16986 | 19565 | 70891846 |
Disseminated aspergillosis | 63.37 | 21.56 | 18 | 17015 | 807 | 70910604 |
Pathogen resistance | 61.88 | 21.56 | 39 | 16994 | 13240 | 70898171 |
Mucosal inflammation | 58.99 | 21.56 | 77 | 16956 | 67773 | 70843638 |
Fall | 58.67 | 21.56 | 17 | 17016 | 444079 | 70467332 |
Off label use | 58.41 | 21.56 | 340 | 16693 | 742720 | 70168691 |
Pain | 58.23 | 21.56 | 40 | 16993 | 628776 | 70282635 |
Fusarium infection | 57.89 | 21.56 | 20 | 17013 | 1712 | 70909699 |
Drug ineffective | 57.88 | 21.56 | 404 | 16629 | 939348 | 69972063 |
Meningoencephalitis herpetic | 56.71 | 21.56 | 20 | 17013 | 1819 | 70909592 |
Bacterial sepsis | 55.66 | 21.56 | 30 | 17003 | 7617 | 70903794 |
Dizziness | 55.65 | 21.56 | 21 | 17012 | 464120 | 70447291 |
Lymphoid tissue hypoplasia | 54.93 | 21.56 | 15 | 17018 | 581 | 70910830 |
Drug resistance | 54.56 | 21.56 | 56 | 16977 | 38134 | 70873277 |
Thymus hypoplasia | 53.90 | 21.56 | 15 | 17018 | 624 | 70910787 |
Enterococcal sepsis | 53.80 | 21.56 | 21 | 17012 | 2536 | 70908875 |
Acute graft versus host disease in liver | 53.41 | 21.56 | 19 | 17014 | 1773 | 70909638 |
Cystitis haemorrhagic | 52.39 | 21.56 | 30 | 17003 | 8563 | 70902848 |
Candida sepsis | 51.89 | 21.56 | 20 | 17013 | 2335 | 70909076 |
Chronic graft versus host disease | 50.51 | 21.56 | 27 | 17006 | 6743 | 70904668 |
Headache | 49.74 | 21.56 | 40 | 16993 | 580365 | 70331046 |
Disseminated cryptococcosis | 49.69 | 21.56 | 18 | 17015 | 1769 | 70909642 |
Tumour lysis syndrome | 49.39 | 21.56 | 41 | 16992 | 21319 | 70890092 |
Bacteraemia | 49.33 | 21.56 | 47 | 16986 | 29262 | 70882149 |
Hypoalbuminaemia | 49.06 | 21.56 | 39 | 16994 | 19083 | 70892328 |
Pneumonia | 48.84 | 21.56 | 276 | 16757 | 595956 | 70315455 |
Engraft failure | 48.82 | 21.56 | 14 | 17019 | 650 | 70910761 |
Aspartate aminotransferase increased | 48.22 | 21.56 | 99 | 16934 | 126879 | 70784532 |
Blood bilirubin increased | 47.49 | 21.56 | 65 | 16968 | 59836 | 70851575 |
Thrombotic microangiopathy | 47.07 | 21.56 | 37 | 16996 | 17811 | 70893600 |
Gastrointestinal fungal infection | 46.40 | 21.56 | 12 | 17021 | 376 | 70911035 |
Cerebral aspergillosis | 46.27 | 21.56 | 17 | 17016 | 1739 | 70909672 |
Staphylococcal sepsis | 44.69 | 21.56 | 32 | 17001 | 13395 | 70898016 |
Liver abscess | 43.67 | 21.56 | 23 | 17010 | 5576 | 70905835 |
Malaise | 43.52 | 21.56 | 25 | 17008 | 432907 | 70478504 |
Renal failure | 43.18 | 21.56 | 121 | 16912 | 188949 | 70722462 |
Weissella infection | 42.72 | 21.56 | 7 | 17026 | 17 | 70911394 |
Acute respiratory distress syndrome | 42.53 | 21.56 | 51 | 16982 | 41203 | 70870208 |
Alanine aminotransferase increased | 42.51 | 21.56 | 103 | 16930 | 147377 | 70764034 |
Nasopharyngitis | 41.80 | 21.56 | 3 | 17030 | 222203 | 70689208 |
Pseudomonal sepsis | 41.08 | 21.56 | 22 | 17011 | 5515 | 70905896 |
Cholestatic liver injury | 40.91 | 21.56 | 20 | 17013 | 4148 | 70907263 |
Product dose omission issue | 40.72 | 21.56 | 3 | 17030 | 217465 | 70693946 |
Renal impairment | 39.86 | 21.56 | 99 | 16934 | 143838 | 70767573 |
Peripheral swelling | 39.74 | 21.56 | 5 | 17028 | 236558 | 70674853 |
Glomerulosclerosis | 39.43 | 21.56 | 13 | 17020 | 964 | 70910447 |
Sinus polyp | 39.40 | 21.56 | 11 | 17022 | 463 | 70910948 |
Pain in extremity | 39.03 | 21.56 | 15 | 17018 | 328067 | 70583344 |
Pleural effusion | 38.51 | 21.56 | 93 | 16940 | 132771 | 70778640 |
White blood cell count decreased | 37.97 | 21.56 | 108 | 16925 | 170033 | 70741378 |
Botulism | 37.14 | 21.56 | 10 | 17023 | 367 | 70911044 |
Mucosal disorder | 36.43 | 21.56 | 17 | 17016 | 3181 | 70908230 |
Alopecia | 36.43 | 21.56 | 3 | 17030 | 198487 | 70712924 |
Neutrophil count decreased | 36.36 | 21.56 | 69 | 16964 | 83487 | 70827924 |
Bacterial infection | 36.31 | 21.56 | 38 | 16995 | 26454 | 70884957 |
Engraftment syndrome | 36.15 | 21.56 | 13 | 17020 | 1251 | 70910160 |
Delayed graft function | 35.86 | 21.56 | 17 | 17016 | 3296 | 70908115 |
Cystitis viral | 35.48 | 21.56 | 11 | 17022 | 669 | 70910742 |
Blast cell count increased | 35.44 | 21.56 | 13 | 17020 | 1324 | 70910087 |
Drug intolerance | 35.06 | 21.56 | 6 | 17027 | 225681 | 70685730 |
Acute lymphocytic leukaemia recurrent | 35.02 | 21.56 | 19 | 17014 | 4885 | 70906526 |
Asthenia | 35.02 | 21.56 | 35 | 16998 | 457631 | 70453780 |
Necrotising oesophagitis | 34.96 | 21.56 | 11 | 17022 | 702 | 70910709 |
Nasal abscess | 34.85 | 21.56 | 8 | 17025 | 150 | 70911261 |
Immunosuppressant drug level increased | 33.81 | 21.56 | 22 | 17011 | 7885 | 70903526 |
Mixed liver injury | 33.31 | 21.56 | 20 | 17013 | 6229 | 70905182 |
Idiopathic pneumonia syndrome | 33.14 | 21.56 | 10 | 17023 | 555 | 70910856 |
Acute myeloid leukaemia | 33.12 | 21.56 | 39 | 16994 | 30901 | 70880510 |
Weight increased | 32.47 | 21.56 | 9 | 17024 | 242322 | 70669089 |
Dyspnoea | 31.85 | 21.56 | 88 | 16945 | 769972 | 70141439 |
Graft versus host disease in gastrointestinal tract | 31.62 | 21.56 | 19 | 17014 | 5925 | 70905486 |
Pulmonary mucormycosis | 31.54 | 21.56 | 11 | 17022 | 968 | 70910443 |
Vascular device infection | 31.08 | 21.56 | 21 | 17012 | 8009 | 70903402 |
Neutropenia | 30.94 | 21.56 | 133 | 16900 | 257023 | 70654388 |
Staphylococcal infection | 30.90 | 21.56 | 50 | 16983 | 53354 | 70858057 |
Cytomegalovirus enterocolitis | 30.57 | 21.56 | 12 | 17021 | 1471 | 70909940 |
Rhinocerebral mucormycosis | 30.27 | 21.56 | 10 | 17023 | 746 | 70910665 |
Klebsiella infection | 30.10 | 21.56 | 26 | 17007 | 14266 | 70897145 |
Graft versus host disease in skin | 29.96 | 21.56 | 18 | 17015 | 5612 | 70905799 |
Enterobacter infection | 29.75 | 21.56 | 16 | 17017 | 4044 | 70907367 |
Lymphocyte count decreased | 29.72 | 21.56 | 44 | 16989 | 43495 | 70867916 |
Biloma | 29.61 | 21.56 | 7 | 17026 | 150 | 70911261 |
Graft versus host disease in liver | 29.56 | 21.56 | 12 | 17021 | 1606 | 70909805 |
Depression | 29.38 | 21.56 | 6 | 17027 | 198968 | 70712443 |
Adenovirus infection | 29.32 | 21.56 | 20 | 17013 | 7748 | 70903663 |
Pruritus | 29.31 | 21.56 | 24 | 17009 | 345536 | 70565875 |
Encephalitis Japanese B | 28.95 | 21.56 | 6 | 17027 | 68 | 70911343 |
Device related infection | 28.69 | 21.56 | 37 | 16996 | 32148 | 70879263 |
Oesophagitis | 28.41 | 21.56 | 31 | 17002 | 22621 | 70888790 |
Nephropathy toxic | 27.99 | 21.56 | 28 | 17005 | 18486 | 70892925 |
Rash morbilliform | 27.89 | 21.56 | 17 | 17016 | 5438 | 70905973 |
Plasma cell leukaemia | 27.87 | 21.56 | 12 | 17021 | 1859 | 70909552 |
Epstein-Barr virus infection | 27.77 | 21.56 | 24 | 17009 | 13174 | 70898237 |
Staphylococcal bacteraemia | 27.14 | 21.56 | 22 | 17011 | 11060 | 70900351 |
Mucosal erosion | 26.60 | 21.56 | 12 | 17021 | 2077 | 70909334 |
Drug hypersensitivity | 26.56 | 21.56 | 15 | 17018 | 262444 | 70648967 |
Hypersensitivity | 26.50 | 21.56 | 11 | 17022 | 229801 | 70681610 |
Pseudomembranous colitis | 26.32 | 21.56 | 16 | 17017 | 5095 | 70906316 |
Neutropenic colitis | 26.31 | 21.56 | 16 | 17017 | 5098 | 70906313 |
Toxicity to various agents | 26.17 | 21.56 | 32 | 17001 | 382140 | 70529271 |
Chest pain | 25.95 | 21.56 | 14 | 17019 | 251246 | 70660165 |
Cytopenia | 25.82 | 21.56 | 26 | 17007 | 17297 | 70894114 |
Blood pressure increased | 25.25 | 21.56 | 7 | 17026 | 188510 | 70722901 |
Blood urea increased | 25.23 | 21.56 | 42 | 16991 | 45867 | 70865544 |
Drug-induced liver injury | 25.23 | 21.56 | 47 | 16986 | 56066 | 70855345 |
Abdominal discomfort | 25.20 | 21.56 | 10 | 17023 | 214648 | 70696763 |
Gait disturbance | 24.55 | 21.56 | 7 | 17026 | 185099 | 70726312 |
Liver disorder | 24.53 | 21.56 | 49 | 16984 | 61519 | 70849892 |
Bacterial toxaemia | 24.23 | 21.56 | 6 | 17027 | 157 | 70911254 |
Kidney fibrosis | 24.17 | 21.56 | 13 | 17020 | 3287 | 70908124 |
Clostridium difficile colitis | 23.79 | 21.56 | 32 | 17001 | 28964 | 70882447 |
Drug ineffective for unapproved indication | 23.55 | 21.56 | 37 | 16996 | 38501 | 70872910 |
Sinusitis fungal | 23.49 | 21.56 | 11 | 17022 | 2074 | 70909337 |
Hypokalaemia | 23.38 | 21.56 | 77 | 16956 | 131111 | 70780300 |
Leukaemia recurrent | 23.36 | 21.56 | 12 | 17021 | 2763 | 70908648 |
Platelet transfusion | 23.33 | 21.56 | 11 | 17022 | 2107 | 70909304 |
Candida test positive | 23.20 | 21.56 | 9 | 17024 | 1069 | 70910342 |
Pulmonary haemorrhage | 23.14 | 21.56 | 22 | 17011 | 13651 | 70897760 |
Brain abscess | 22.76 | 21.56 | 14 | 17019 | 4552 | 70906859 |
Aspergillus test positive | 22.70 | 21.56 | 8 | 17025 | 726 | 70910685 |
Device related sepsis | 22.22 | 21.56 | 15 | 17018 | 5713 | 70905698 |
Gamma-glutamyltransferase increased | 22.22 | 21.56 | 42 | 16991 | 50643 | 70860768 |
Reactive gastropathy | 21.98 | 21.56 | 7 | 17026 | 465 | 70910946 |
Oral disorder | 21.93 | 21.56 | 18 | 17015 | 9211 | 70902200 |
Blood lactate dehydrogenase increased | 21.85 | 21.56 | 34 | 16999 | 35093 | 70876318 |
Myocardial infarction | 21.84 | 21.56 | 7 | 17026 | 171638 | 70739773 |
Hyperbilirubinaemia | 21.79 | 21.56 | 27 | 17006 | 22541 | 70888870 |
Viral haemorrhagic cystitis | 21.69 | 21.56 | 10 | 17023 | 1821 | 70909590 |
Oral fungal infection | 21.66 | 21.56 | 12 | 17021 | 3214 | 70908197 |
None
Source | Code | Description |
---|---|---|
ATC | J02AX05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use |
FDA CS | M0519359 | Lipopeptides |
FDA EPC | N0000175507 | Echinocandin Antifungal |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000935 | Antifungal Agents |
CHEBI has role | CHEBI:35441 | antiinfective agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Candidiasis of the esophagus | indication | 20639004 | DOID:13146 |
Disseminated candidiasis | indication | 70572005 | |
Candidal septicemia | indication | 187022007 | |
Candidemia | indication | 432261003 | |
Prevention of Disseminated Candidiasis | indication | ||
Candida Peritonitis | indication | ||
Oropharyngeal Candidiasis | off-label use | ||
Intravascular hemolysis | contraindication | 15601008 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Liver function tests abnormal | contraindication | 166603001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.09 | acidic |
pKa2 | 10.7 | acidic |
pKa3 | 12.91 | acidic |
pKa4 | 13.44 | acidic |
pKa5 | 13.52 | acidic |
pKa6 | 13.9 | acidic |
pKa7 | 13.91 | acidic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 100MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | June 27, 2006 | RX | INJECTABLE | INTRAVENOUS | Dec. 20, 2022 | TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE |
EQ 50MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | March 16, 2005 | RX | INJECTABLE | INTRAVENOUS | Dec. 20, 2022 | TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE |
EQ 100MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | June 27, 2006 | RX | INJECTABLE | INTRAVENOUS | June 20, 2023 | PEDIATRIC EXCLUSIVITY |
EQ 50MG BASE/VIAL | MYCAMINE | ASTELLAS | N021506 | March 16, 2005 | RX | INJECTABLE | INTRAVENOUS | June 20, 2023 | PEDIATRIC EXCLUSIVITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1,3-glucan synthase catalytic subunit 1 | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-1,3-glucan synthase | Unclassified | WOMBAT-PK |
ID | Source |
---|---|
D02465 | KEGG_DRUG |
208538-73-2 | SECONDARY_CAS_RN |
4024920 | VANDF |
4024948 | VANDF |
C1120386 | UMLSCUI |
CHEBI:600520 | CHEBI |
CHEMBL1237070 | ChEMBL_ID |
CHEMBL457547 | ChEMBL_ID |
D000077551 | MESH_DESCRIPTOR_UI |
DB01141 | DRUGBANK_ID |
8069 | INN_ID |
R10H71BSWG | UNII |
477468 | PUBCHEM_CID |
325887 | RXNORM |
19567 | MMSL |
334346 | MMSL |
66902 | MMSL |
d05487 | MMSL |
010714 | NDDF |
010715 | NDDF |
416127003 | SNOMEDCT_US |
416233001 | SNOMEDCT_US |
426226002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9361 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0143-9362 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3211 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Mycamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0469-3250 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-190 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 29 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-190 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 29 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-191 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 29 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-191 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 29 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-229 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | NDA | 26 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-230 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | NDA | 26 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6119 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6120 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 27 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-728 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-728 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-729 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-729 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-729 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-036 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | ANDA | 34 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-037 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 20 mg | INTRAVENOUS | ANDA | 34 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-028 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-029 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 30 sections |
Micafungin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72572-427 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 100 mg | INTRAVENOUS | ANDA | 34 sections |